What is small molecule manufacturing?
Small molecule manufacturing is the process of producing low-molecular-weight pharmaceutical compounds as consistent, quality-controlled drug products. It typically includes formulation development, analytical testing, scale-up, technology transfer, batch manufacturing, packaging or labeling where applicable, and documentation for regulatory review. The goal is to create a reproducible product that meets defined quality, safety, performance, and stability requirements at the intended production scale.
What is the rule of 5 for small molecules?
The Rule of 5, commonly called Lipinski’s Rule of Five, is a drug-likeness guideline used during discovery and development. It generally considers molecular weight, lipophilicity, hydrogen-bond donors, and hydrogen-bond acceptors to estimate the likelihood of oral absorption. It is not a manufacturing rule or a guarantee of success; many effective medicines fall outside these parameters.
What services does a small molecule CDMO provide?
A small molecule CDMO can support the product lifecycle from early formulation design through commercial manufacturing. Typical capabilities include formulation optimization, analytical method development and validation, stability planning, technology transfer, exhibit or registration batch manufacturing, commercial supply planning, and regulatory documentation. DRK Research Solutions also supports eCTD dossier preparation and submission activities for regulated-market product programs.
What is the difference between a CDMO and a CMO?
A CMO primarily provides manufacturing services based on an established process and product specification. A CDMO combines contract development and manufacturing, contributing technical work before production begins. This can include formulation development, analytical method work, scale-up strategy, technology transfer, and regulatory support. A CDMO model helps connect early development choices with later manufacturing and submission requirements.
Can DRK support generic and hybrid small molecule products?
Yes. DRK Research Solutions provides CDMO services for generic and hybrid product development intended for regulated markets. Support spans formulation development and optimization, analytical method development, technology transfer, exhibit and commercial batch manufacturing, and eCTD dossier preparation. The service model is designed to connect technical development with the documentation and supply considerations needed for market authorization.
How does technology transfer support small molecule manufacturing?
Technology transfer moves product knowledge, methods, specifications, and manufacturing processes from development into a manufacturing facility or between sites. A well-managed transfer confirms that critical process parameters, analytical procedures, equipment needs, and quality controls are understood and reproducible. This reduces avoidable variation during scale-up and helps establish a consistent foundation for exhibit, registration, or commercial batches.
What documentation is needed for a small molecule regulatory submission?
Requirements vary by market and product, but submissions commonly require product development summaries, manufacturing process information, specifications, analytical method data, validation evidence, stability information, batch records, and quality controls. DRK Research Solutions supports preparation of eCTD Module 2–5 dossiers, helping sponsors organize technical content for regional and international regulatory review.
When should a sponsor engage a small molecule CDMO?
Engage a CDMO early when formulation feasibility, analytical methods, scale-up planning, or a clear regulatory pathway need to be developed in parallel. Early involvement can help align the product target profile with practical manufacturing controls and documentation requirements. Sponsors may also engage a CDMO later for technology transfer, exhibit batches, commercial manufacturing, or dossier support.